NR2F6 and neoplasm: Given the lack of human genetic data on the role of NR2F6 as a suppressor of effective cancer immunity and the current situation that not all therapeutics developed in murine tumor models achieve similar success in the clinic, the fate of NR2F6-based immuno-oncology therapy envisioned here ultimately depends on establishing functional antagonists for NR2F6 and their outcome in human clinical trials.